Á¤º¸¿µ(Joung Bo-Young) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
Ventricular tachycardia (VT) is an important cause of sudden death and morbidity in patients with structural heart disease. An implantable cardioverter defibrillator (ICD) can terminate VT when it occurs and is the firstline therapy for most high risk patients. After a spontaneous episode of VT or ventricular fibrillation (VF) and ICD implantation, 40% to 60% of patients experience recurrent VT. A first episode of VT occurs in 2.5% to 12% of patients with ICDs implanted for primary prevention of sudden death. ICD shocks reduce quality of life and are associated with an increased risk of heart failure and death, requiring therapy to prevent episodes. Antiarrhythmic drug therapy with amiodarone or sotalol reduces episodes of VT but with side effects and only modest efficacy. Catheter ablation can reduce the frequency of VT episodes and can be life saving when VT is incessant.
Å°¿öµå
ventricular tachycardia, structural heart disease, implantable cardioverter defibrillator
KMID :
1011920100110010020
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
An implantable cardioverter defibrillator (ICD) can terminate VT when it occurs and is the firstline therapy for most high risk patients.